二氯化四(二甲基亞碸)合釕(II)
Dichlorotetrakis(dimethyl sulfoxide) ruthenium (II) | |||
---|---|---|---|
| |||
系統名 Ruthenium, dichlorotetrakis(sulfinylbis(methane))- (9CI) | |||
別名 | 二氯四(二甲亞碸)合釕 四(二甲基亞碸)二氯化釕 氯化四(二甲基亞碸)合釕(II) | ||
識別 | |||
CAS號 | 41290-68-0(S,S,S,O) 59091-96-2(cis-S,S,S,O) 89395-66-4(S,S,S,S) 64376-67-6(cis-S,S,S,S) 72904-47-3(trans-S,S,S,S) 75766-08-4(trans-S,S,S,O) | ||
性質 | |||
化學式 | C8H24Cl2O4RuS4 | ||
莫耳質量 | 484.51 g·mol−1 g·mol⁻¹ | ||
外觀 | 黃色晶體 | ||
溶解性(水) | 易溶於水 | ||
溶解性 | 硝基甲烷、二氯甲烷、氯仿1 | ||
結構 | |||
配位幾何 | 八面體配位 | ||
若非註明,所有數據均出自標準狀態(25 ℃,100 kPa)下。 |
二氯化四(二甲基亞碸)合釕(II)是一種配位化合物,化學式為RuCl2(DMSO)4,其中,DMSO為二甲基亞碸的英文縮寫。它存在順式和反式兩種構型,這兩種構型都是已知的,但順式構型(如右圖)更為常見。順式異構體為黃色固體,在空氣中穩定,可溶於一部分有機溶劑。它是潛在的抗癌藥物。
結構與製備
順式異構體為DMSO配體連接異構。[1]三個DMSO配體為S-鍵合,另一個為O-鍵合,對於兩個Cl來說是順式構型。反式異構體也是黃色的,但四個DMSO配體都是S-鍵合的。順式可以通過熱反應得到,而反式由順式通過紫外線照射得到。[2]
這些配合物最初由三氯化釕的DMSO溶液在氫氣氣氛中加熱得到。[3]另一種不使用氫氣的方法也得到了文獻報道。[2][4]
反應
順式RuCl2(DMSO)4和乙醯丙酮、碳酸氫鈉在乙醇中回流反應,經提純後可以得到黃色的順式二(乙醯丙酮)二(二甲基亞碸)合釕(II)(cis-Ru(DMSO)2(acac)2)。[5]它和苯胺在常溫下甲醇-氯仿(2:1)中反應,配位原子為氧的DMSO配體被取代,得到淺黃色的cis,fac-[RuCl2(DMSO)3(NH2C6H5)];若在甲醇中回流反應,則配位原子為氧和硫的兩個DMSO配體被取代,得到深黃色的trans,cis,cis-[RuCl2(DMSO)2(NH2C6H5)2]。[6]
潛在應用
RuCl2(DMSO)4最初於20世紀80年代早期被認定為抗癌藥。[7]後期進一步的研究[8][9]使得其它含DMSO的釕化合物得到了開發,其中一些進行了早期的臨床試驗。[10]
參考文獻
- ^ Enzo Alessio. Synthesis and reactivity of Ru-, Os-, Rh-, and Ir-halide-sulfoxide compounds. Chem. Rev. 2004, 104 (9): 4203–4242. doi:10.1021/cr0307291.
- ^ 2.0 2.1 I. Bratsos; E. Alessio. Ruthenium(II) Chloro Complexes of dimethylsulfoxide. Inorganic Syntheses. 2010, 35: 148–152. doi:10.1002/9780470651568.ch8.
- ^ B. R. James; E. Ochiai; G.I. Rempel. Ruthenium (II) halide dimethylsulphoxide complexes from hydrogenation reactions. Inorganic and Nuclear Chemistry Letters. 1971, 7 (8): 781–784. doi:10.1016/0020-1650(71)80091-0.
- ^ Nagy, E. M.; Pettenuzzo, A. Ruthenium(II/III)-Based Compounds with Encouraging Antiproliferative Activity against Non-small-Cell Lung Cancer. Chemistry: A European Journal. 2012, 18: 14464–14472. doi:10.1002/chem.201202171.
- ^ Adam Wu, David C Kennedy, Brian O Patrick, Brian R James. Ruthenium(II) acetylacetonato–sulfoxide complexes. Inorganic Chemistry Communications. 2003-08, 6 (8): 996–1000 [2021-08-25]. doi:10.1016/S1387-7003(03)00164-3. (原始內容存檔於2020-02-07) (英語). (頁面存檔備份,存於網際網路檔案館)
- ^ Daniele M. Martins, Pedro I. S. Maia, Valdemiro P. Carvalho-Jr, Benedito S. Lima-Neto. Cooperative Effects of Aniline with DMSO in Ru II Complexes: Tuning the Reactivity for Ring-Opening Metathesis Polymerization: Cooperative Effects of Aniline with DMSO in Ru II Complexes: Tuning the Reactivity for Ring-Opening Metathesis Polymerization. European Journal of Inorganic Chemistry. 2019-11-10, 2019 (41): 4421–4426 [2021-08-25]. doi:10.1002/ejic.201900887 (英語).
- ^ Sava, Gianni; Giraldi, Tullio; Mestroni, Giovanni; Zassinovich, Grazia. Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichlorodiammino platinum(II) in mice bearing Lewis lung carcinoma. Chemico-Biological Interactions. July 1983, 45 (1): 1–6. doi:10.1016/0009-2797(83)90037-6.
- ^ Coluccia, Mauro; Sava, Gianni; Loseto, Francesco; Nassi, Anna; Boccarelli, Angela; Giordano, Domenico; Alessio, Enzo; Mestroni, Giovanni. Anti-leukaemic action of RuCl2(DMSO)4 isomers and prevention of brain involvement on P388 leukaemia and on subline. European Journal of Cancer. January 1993, 29 (13): 1873–1879. doi:10.1016/0959-8049(93)90541-M.
- ^ Bratsos, I; Serli, B; Zangranko, E; Katsaros, N; Alessio, E. Replacement of chlorides with dicarboxylate ligands in anticancer active Ru(II)-DMSO compounds: A new strategy that might lead to improved activity. Inorg. Chem. 2007, 46 (3): 975–992. PMID 17257042. doi:10.1021/ic0613964.
- ^ Enzo Alessio, Bentham Science Publisher; Giovanni Mestroni, Bentham Science Publisher; Alberta Bergamo, Bentham Science Publisher; Gianni Sava, Bentham Science Publisher. Ruthenium Antimetastatic Agents. Current Topics in Medicinal Chemistry. 1 November 2004, 4 (15): 1525–1535. doi:10.2174/1568026043387421.